Avacta Group (AVCT) Competitors GBX 28 -0.25 (-0.88%) As of 11:49 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesBuy This Stock AVCT vs. SLN, PRTC, OXB, FARN, HZD, VRP, ARIX, BVXP, 4BB, and CIRShould you be buying Avacta Group stock or one of its competitors? The main competitors of Avacta Group include Silence Therapeutics (SLN), PureTech Health (PRTC), Oxford Biomedica (OXB), Faron Pharmaceuticals Oy (FARN), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Bioventix (BVXP), 4basebio (4BB), and Circassia Group (CIR). These companies are all part of the "biotechnology" industry. Avacta Group vs. Silence Therapeutics PureTech Health Oxford Biomedica Faron Pharmaceuticals Oy Horizon Discovery Group plc (HZD.L) Verona Pharma plc (VRP.L) Arix Bioscience Bioventix 4basebio Circassia Group Avacta Group (LON:AVCT) and Silence Therapeutics (LON:SLN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, community ranking, dividends, analyst recommendations, institutional ownership and valuation. Which has better earnings and valuation, AVCT or SLN? Silence Therapeutics has lower revenue, but higher earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvacta Group£26.29M4.05-£30.08M-£7.77-3.60Silence Therapeutics£11.35M0.00N/A-£48.60N/A Does the MarketBeat Community prefer AVCT or SLN? Avacta Group received 9 more outperform votes than Silence Therapeutics when rated by MarketBeat users. However, 68.81% of users gave Silence Therapeutics an outperform vote while only 67.30% of users gave Avacta Group an outperform vote. CompanyUnderperformOutperformAvacta GroupOutperform Votes21267.30% Underperform Votes10332.70% Silence TherapeuticsOutperform Votes20368.81% Underperform Votes9231.19% Is AVCT or SLN more profitable? Silence Therapeutics has a net margin of 0.00% compared to Avacta Group's net margin of -114.45%. Silence Therapeutics' return on equity of 0.00% beat Avacta Group's return on equity.Company Net Margins Return on Equity Return on Assets Avacta Group-114.45% -74.00% -21.80% Silence Therapeutics N/A N/A N/A Do institutionals and insiders hold more shares of AVCT or SLN? 10.2% of Avacta Group shares are owned by institutional investors. 32.9% of Avacta Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor AVCT or SLN? In the previous week, Avacta Group had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 1 mentions for Avacta Group and 0 mentions for Silence Therapeutics. Avacta Group's average media sentiment score of 0.75 beat Silence Therapeutics' score of 0.00 indicating that Avacta Group is being referred to more favorably in the media. Company Overall Sentiment Avacta Group Positive Silence Therapeutics Neutral SummaryAvacta Group beats Silence Therapeutics on 8 of the 12 factors compared between the two stocks. Get Avacta Group News Delivered to You Automatically Sign up to receive the latest news and ratings for AVCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVCT vs. The Competition Export to ExcelMetricAvacta GroupBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£106.38M£128.48M£5.31B£2.62BDividend Yield3.97%3.74%5.20%5.05%P/E Ratio-3.603.4126.69134.81Price / Sales4.054,169.40393.58221,342.27Price / Cash15.0013.1938.2528.03Price / Book1.9033.216.743.84Net Income-£30.08M-£91.56M£3.23B£5.88B7 Day Performance-15.15%2.85%0.01%3.52%1 Month Performance-15.15%7.44%8.69%25.34%1 Year Performance-36.36%101.47%18.36%130.33% Avacta Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVCTAvacta GroupN/AGBX 28-0.9%N/A-30.9%£106.38M£26.29M-3.60120News CoverageSLNSilence TherapeuticsN/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading VolumePRTCPureTech Health1.3048 of 5 starsGBX 129.44+6.4%GBX 455+251.5%-40.7%£388.81M£521,320.79-5.31300OXBOxford Biomedica1.3147 of 5 starsGBX 294.90+1.0%GBX 560+89.9%-7.6%£313.48M£98.31M-2.19891FARNFaron Pharmaceuticals OyN/AGBX 228+3.6%N/A+4.3%£306.09MN/A-6.1034HZDHorizon Discovery Group plc (HZD.L)N/AN/AN/AN/A£302.98M£54.63M-33.55416VRPVerona Pharma plc (VRP.L)N/AN/AN/AN/A£228MN/A-1.6822Gap UpARIXArix BioscienceN/AN/AN/AN/A£183.73M£14.16M1,290.919BVXPBioventixN/AGBX 2,852.50-0.8%N/A-33.7%£149.37M£13.65M18.4512News Coverage4BB4basebioN/AGBX 1,150+2.2%GBX 1,600+39.1%-20.7%£147.32M£311,000.00-1,474.36101News CoverageCIRCircassia GroupN/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap Down Related Companies and Tools Related Companies Silence Therapeutics Alternatives PureTech Health Alternatives Oxford Biomedica Alternatives Faron Pharmaceuticals Oy Alternatives Horizon Discovery Group plc (HZD.L) Alternatives Verona Pharma plc (VRP.L) Alternatives Arix Bioscience Alternatives Bioventix Alternatives 4basebio Alternatives Circassia Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:AVCT) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avacta Group Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Avacta Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
